Colorectal Cancer, Lung Metastases
Conditions
Brief summary
The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation) and recurrence of lung metastases.
Detailed description
The investigators produce customized gene target panel by selecting genes that are commonly found in colorectal cancer and metastasis from existing literature. In patients diagnosed with lung metastases from colorectal cancer, 20mL of whole blood is collected before and after local treatment (surgery or radiation) and cell-free DNA (cfDNA) is extracted from the collected blood. Thereafter, 20 mL of whole blood is additionally collected once after 3 months (±2 months) and once after 6 months (±2 months) during follow-up and cfDNA is extracted. The investigators perform sequencing from the extracted cfDNA. The investigators compare the mutations detected in cfDNA before and after local treatment and identify the trend of reducing mutations in cfDNA after local treatment. So The investigators discover biomarkers for the outcome of local treatment. The investigators also search for mutations for target drugs from mutation profiling of cfDNA.
Interventions
OTHERDiagnostic Test: liquid biopsy
detection of tumor DNA alteration in cf-DNA
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. adults over 19 years of age 2. those who understand research and have written consent 3. cases diagnosed with lung metastases from colorectal cancer
Exclusion criteria
1. pregnant women, nursing women 2. those who lack the ability to voluntarily agree 3. participation in other clinical trials where drugs for clinical trials are administered within the past four weeks as of the date of participation in clinical trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| correlation between circulating tumor DNA (ctDNA) before and after local treatment (surgery or radiation) and recurrence of lung metastases from colorectal cancer | about 6 month but additional extension for patients with relapse after local treatment | The investigations investigate whether ctDNA changes and f/u ctDNA fraction after local treatment (surgery or radiation) can be useful as markers to predict the outcome of local treatments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mutations related to target drug | about 6 month but additional extension for patients with relapse after local treatment | The investigations check for target drug related mutations from mutation profiling of ctDNA. |
Countries
South Korea
Contacts
Primary ContactSeung-Tae Lee
Outcome results
None listed